Home
About
FAQ
History (23)
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q).
APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume.
Instruction Across an Educational Spectrum as a Tool for Building Teaching Skills in the Biomedical Sciences
Adenine Phosphoribosyltransferase
Detection of lineage-reprogramming efficiency of tumor cells in a 3D-printed liver-on-a-chip model.
See All 23 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Search Results (46)
More Search Options
Sort
Query Relevance
Name (A-Z)
Name (Z-A)
Institution (A-Z)
Institution (Z-A)
Show
(choose columns)
Faculty Rank
Name
Institution
Why
Omar P. Sangueza MD
Wake Forest School of Medicine
Why?
Kristen A. Zeller MD
Wake Forest School of Medicine
Why?
Marissa M. Howard-McNatt MD
Wake Forest School of Medicine
Why?
Joseph L. Jorizzo MD
Wake Forest School of Medicine
Why?
Kimberly A. Stogner MD
Wake Forest School of Medicine
Why?
David A. Kunkle MD
Wake Forest School of Medicine
Why?
Peter E. Clark MD
Wake Forest School of Medicine
Why?
Edward H. Kincaid MD
Wake Forest School of Medicine
Why?
Ashok K. Hemal MD
Wake Forest School of Medicine
Why?
Twinkle K. Pandian MD, MPH
Wake Forest School of Medicine
Why?
Hafiz S. Patwa MD, PharmD
Wake Forest School of Medicine
Why?
Gopal H. Badlani MD
Wake Forest School of Medicine
Why?
John A. Wilson MD, FAANS, FACS
Wake Forest School of Medicine
Why?
Julie A. Freischlag MD, FACS, FRSCE
Wake Forest School of Medicine
Why?
Jill Ohar MD
Wake Forest School of Medicine
Why?
Per Page
15
25
50
100
Page
of 4
Next
Prev
Search Criteria
Neoplasms Multiple Primary
Click "Why?" to see why a person matched the search.
Search Options
Modify Search
Search Other Institutions